Healios

Executive Summary

Healios is a Japanese biotechnology company at the forefront of regenerative medicine, leveraging induced pluripotent stem cell (iPSC) technology to address major unmet medical needs. The company's pipeline focuses on three key areas: ophthalmology (age-related macular degeneration, AMD), acute respiratory distress syndrome (ARDS), and oncology (engineered natural killer cells for solid tumors). Healios has advanced its iPSC-derived retinal pigment epithelium (iPSC-RPE) therapy into Phase 2 trials for AMD, and its somatic stem cell therapy for ARDS is under clinical evaluation in Japan. The oncology program, utilizing eNK cells, is in early-stage development. With a strong IP portfolio and strategic partnerships, Healios aims to become a leader in cell therapy.

Upcoming Catalysts (preview)

• H2 2026Phase 2 topline data for iPSC-RPE in AMD50% success
• Q1 2027Regulatory update for ARDS cell therapy in Japan60% success
• Q4 2026IND or early data for eNK cell therapy in solid tumors40% success